Differently from the high-dose IL-2 protocols used for the treatment of cancer patients (i.e., > 108 IU/day) that associate with elevated toxicity,[60] the use of low-dose IL-2 in SLE is well-tolerated and beneficial on multiple disease manifestations and does not associate with generalized immune suppression.[61] Therefore, low-dose IL-2 could become a valuable synergizing complement to current therapies in SLE (although likely insufficient as monotherapy to halt a complex disease such as SLE). The gene discussed is IL2; the disease is systemic lupus erythematosus.